December 14, 2020 6:13pm

Increasing fears of new lockdowns and residual fears as a lot of scar tissue will cover the site of injury, volatility. “Scars can take up to 1 year to mature fully and go through four stages of healing” – so goes the market. Understand the percentage of Americans to be infused and the phase period of times will not happen as quick as we hope

Pre-open indication results: 9 HITs and 0 MISS,

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I track the numbers, so there’s no question re my opinion; so, you can do what others can't.

Closing explanations on what you need to know for the next week!

The Dow closed DOWN -184.82 points (-0.62%); the S&P closed DOWN -15.97 points (-0.44%) while the Nasdaq closed UP +62.17 points (+0.50%)

 

Henry’omics:

Two indexes (Dow and S&P) fell as sentiment got stomped …

Yet, the arm needle TV shots set a roll-out (a short-term image) beginning and (near and long-term) hope of stemming the virus’s infection.

Although it is very interesting the juxtaposition of shut-downs increasing that has only moderated the stock market!

 

All-time highs:

  • XBI at 146.05, IBB at 153.63, Cellectis SA (CLLS) at $32.00, Precigen (PGEN) at $9.26, Intellia Therapeutics (NTLA) at $56.93 and Fate Therapeutics (FATE) at $98.50

Hammered in today’s market:

  • ReNeuron (RENE.L), uniQure NV (QURE), Intellia Therapeutics (NTLA), Solid Biosciences (SLDB), Editas Medicine (EDIT) to name 5 of the 11 declining of the 35 covered

 

Jumping with share pricing momentum: 

  • Ultragenyx (RARE), Chinook Therapeutics (KDNY), Alnylam Pharmaceuticals (ALNY), Global Blood Therapeutics (GBT), bluebird bio (BLUE) name 5 of the 23 inclining of the 35 covered

 

Pre-open indication: 9 HITs <BUY on News: Brainstorm Cell Therapeutics (BCLI +$0.52), BUY from SELL: BioLife Solutions (BLFS +$0.32), Cellectis SA (CLLS +$1.70), Homology Medicine (FIXX +$1.74), Sage Therapeutics (SGMO +$1.64), Sangamo Therapeutics (SGMO +$0.80)>; PUMPED: Biostage (BSTG +$0.01 to $1.35 with 545 shares traded): SKIM and TRIM: <CRISPER Therapeutics (CRSP +$1.65), Editas Medicine (EDIT -$0.43) and 0 MISS

 

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: follow the bouncing share pricing after Friday’s decline. Vaccine shipments also begins “truckin” sentiment” … https://www.regmedinvestors.com/articles/11676  

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Monday opened positive at 29/5 and 1 flat, stayed positive at the mid-day at 28/5 and 2 flats, closing positive at 23/11 and 1 flat;
  • Friday opened negative at 10/21 and 4 flats, stayed negative at the mid-day at 12/21 and 2 flats, closing negative at 13/20 and 2 flats;

 

Key metrics:

  • Sector volume INCREASED with 18 of the 23-upside having higher than the 3-month average volume with the increased volume of 8 of 11-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 23-upside were +0.60% (RGNX) to +23.12% (KDNY) while the 11-downside of -0.41% (MESO) to -14.62% (SLDB);

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed up +2.34% and XBI closed up +2.66%
  • Friday, the IBB closed up +0.25% and XBI closed down -0.06%

 

Monday’s (10 of 23) incliners:

  • Ultragenyx (RARE +$8.28 after Friday’s +$10.75);
  • Chinook therapeutics (KDNY +$3.08);
  • Alnylam Pharmaceuticals (ALNY +$3.04 after Friday’s +$3.60);
  • Global Blood Therapeutics (GBT +$2.13);
  • bluebird bio (BLUE +$2.09);
  • Ionis Pharmaceuticals (IONS +$2.02 after Friday’s -$0.57
  • Homology Medicine (FIXX +$1.74 after Friday’s +$0.35);
  • Cellectis SA (CLLS +$1.70 after Friday’s -$0.71
  • CRISPR Therapeutics (CRSP +$1.65 after Friday’s -$5.85
  • Sage Therapeutics (SAGE +$1.64 after Friday’s -$0.63);

Monday’s (11 of 11) decliner:

  • ReNeuron (RENE.L -$3.00 after Friday’s +$4.00);
  • uniQure NV (QURE -$1.37 after Friday’s -$0.37);
  •  Intellia Therapeutics (NTLA -$1.16 after Friday’s -$2.60
  • Solid Biosciences (SLDB -$0.82 after Friday’s +$1.91);
  • Editas Medicine (EDIT -$0.43 after Friday’s -$4.92
  • AxoGen (AXGN -$0.22);
  • Vericel (VCEL -$0.22 after Friday’s -$0.49);
  • Caladrius Biosciences (CLBS -$0.19);
  • Verastem (VSTM -$0.12);
  • Applied Genetic Technologies (AGTC -$0.04 after Friday’s +$0.49);

Closing 1– Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Monday’s percentage (%) of the 23-upside were +0.60% (RGNX) to +23.12% (KDNY) while the 11-downside of -0.41% (MESO) to -14.62% (SLDB);
  • Friday’s percentage (%) of the 13-upside were +0.27% (BLFS) to +51.62% (SLDB) while the 20-downside ranges from -0.35% (BLUE) to -21.53% (SGMO);

 

Sentiment and a few daily indicators:

The arrival of a long-awaited vaccine offers the “promise” of a return to normality (what’s that?) in the coming New Year, but we NEED to maintain safety measures (masks and distance0 until the drug is fully distributed.

Infection cases <Million>:

  • Monday 16.25 M cases
  • Friday 15.61 M cases

Monday’s death rate totaled 299,191 after Friday’s 292,190, Thursday’s 289,451, Wednesday’s 287,550, Tuesday’s 284,887 and last Monday’s 282,522 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Monday: 18 out of the 23-upside had higher than the 3-month average volume;
  • Friday: 8 out of the 13-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +1.41 points or +6.05% at 24.72
  • Friday was up +0.79 points or +3.51% at 23.31

Downside volume:

  • Monday: 8 out of the 13-downside had higher than the 3-month average volume;
  • Friday: 7 out of the 20-downside had higher than the 3-month average volume;

 

December, the 3rd month of Q4 …

Monday (1214) closed positive with 23 advancers, 12 decliners and 1 flat 

Friday closed negative with 13 advancers, 20 decliners and 2 flats 

Thursday closed positive with 22 advancers, 9 decliners and 4 flats 

Wednesday closed negative with 10 advancers, 22 decliners and 3 flats 

Tuesday closed positive with 19 advancers, 14 decliners and 2 flats 

Monday (12/7) closed negative with 14 advancers, 20 decliners and 1 flat 

Friday closed positive with 25 advancers, 9 decliners and 2 flats 

Thursday closed neutral with 16 advancers, 16 decliners and 3 flats 

Wednesday closed positive with 20 advancers, 14 decliners and 1 flat 

Tuesday (12/1) closed positive with 20 advancers, 15 decliners and 1 flat 

 

The Bottom Line: Reiterating, “Optimism (a non-quantifiable factor) sinks as near-term fiscal stimulus deal fades thus a market slip…”

Although, “The House and Senate passed a one-week federal spending extension to avoid a shutdown through Dec. 18 to buy more time to reach a stimulus agreement.”

As I have stated, “When the wind blows, there are times to move with it”. However, it was time to … “show me the money”.

Again, when the oversold get ripe – it’s time to recognize value by selling a “portion” of our holdings while still maintaining a basic position.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.